Loading…

C-D2-02: Integrating Clinical Trial Findings Into Practice Through Risk Stratification: The Case of Heart Failure Management

Background: Heart failure case management programs have been shown to be highly effective at preventing future hospitalizations in clinical trials. But these programs absolute benefits depend on the baseline risk of outcome in the treated population. Since baseline risks of hospitalization in trials...

Full description

Saved in:
Bibliographic Details
Published in:Clinical medicine & research 2010-03, Vol.8 (1), p.36-36
Main Authors: Smith, D. H, Johnson, E. S, Thorp, M. L, Crispell, K. A, Yang, X., Petrik, A. F
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Heart failure case management programs have been shown to be highly effective at preventing future hospitalizations in clinical trials. But these programs absolute benefits depend on the baseline risk of outcome in the treated population. Since baseline risks of hospitalization in trials are often higher than community-based samples, translating trial results to the community setting may be misleading. One solution is to identify subgroups for intervention that have sufficiently high baseline risk. Objective: Using estimates of hospitalizations averted from a previously published systematic review of heart failure (HF) management we estimated a program’s efficiency based on level of predicted risk. Methods: Medical history and demographic data on HF patients from a large integrated US health plan were used to build a prognostic risk-score for cardiovascular-related hospitalization over 1-year. We calculated the crude rate of hospitalizations for comparison with trial data. We also calculated the program’s potential dollar savings from averting hospitalizations. Results: The average risk for hospitalization in the systematic review’s trials was 45%; our population’s average observed risk was 18% and the risk among the highest risk patients was 33%. After accounting for the intervention cost, the base-case analysis shows a savings of $122/patient at highest risk. Failing to intervene according to predicted risk (no targeting) would actually cost $211/patient. Conclusion: Our findings illustrate how clinical trial findings can be efficiently integrated into community-settings by using a prognostic risk score to focus attention on high-risk subgroups.
ISSN:1539-4182
1554-6179
DOI:10.3121/cmr.8.1.36-b